JPMorgan Downgrades Century Therapeutics (IPSC) to Neutral 'in view of Lengthy Timelines to Meaningful POC for Lead CNTY-101'
Tweet Send to a Friend
(Updated - August 28, 2023 4:33 AM EDT)
JPMorgan analyst Eric Joseph downgraded Century Therapeutics (NASDAQ: IPSC) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Eric Joseph downgraded Century Therapeutics (NASDAQ: IPSC) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
